Market Research Report
Transcriptomics Market by Type, Technology, Application : Global Opportunity Analysis and Industry Forecast, 2021-2030
|Transcriptomics Market by Type, Technology, Application : Global Opportunity Analysis and Industry Forecast, 2021-2030|
Published: February 27, 2022
Allied Market Research
Content info: 215 Pages
Delivery time: 2-3 business days
The transcriptomics market was valued at $5,790.51 million in 2020, and is estimated to reach $11,397.08million by 2030, growing at a CAGR of 7.0% from 2021 to 2030.Transcriptomics is the collection and study of RNA present in different types of cells and tissues in an organism. It is a promising tool for discovery of basic gene expression patterns, determination of drug-induced toxicity in adverse drug reactions, and other uses in the medical field. It is an analysis of transcriptome. RNA performs many functions within the cell and studying the transcriptome provides insights into how genes are working and whether proteins are being produced.
Increase in advancements in the field of transcriptomics such as extensive use of RNA-sequencing and rise in application of transcriptomics such as drug discovery are expected to drive the growth of the market. Moreover, other factors that fuel the market growth include increase in adoption of transcriptomics products and rise in demand for personalized medicine. In addition, many companies have increased their market presence, thereby expanding their business across new markets. For instance, in February 2020, Dovetail Genomics announced the launch of its Dovetail HichlP and Micro-C kits. These aforementioned factors have led to increase in the growth of the transcriptomics market.
Furthermore, the high demand for diagnostic of inflammatory diseases such as COVID-19, and rise in production of transcriptomics instruments to boost the growth of the market. In addition, in February 2020, Caris Life Sciences launched its new MI transcriptome, which enables whole transcriptome sequencing. MI transcriptome uses the high capability of sequencing to gain insight into the RNA profiles of tumor patients. Thus, increased availability of transcriptomics instruments propels the growth of the transcriptomics market.
Conversely, high capital investment in the implementation of transcriptomics is anticipated to hinder the market growth. People, nowadays are more aware of health, which, in turn, compels them to maintain their health condition and increase demand for diagnosis of various diseases. This has further encouraged many key players to enter emerging markets, thus offering a lucrative growth opportunity in the transcriptomics market.
The global transcriptomics market is segmented on the basis of type, technology, application, and region. By type, the market is categorized into consumables, instruments, software, and services.
On the basis of technology, the market is divided into microarrays, q PCR, and sequencing technology.
Depending on application, it is fragmented into drug discovery, diagnostics, disease profiling, and others. On the basis of end user, it is divided into government institutes & academic centers, pharmaceutical & biotechnology companies and contract research organizations. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Some of the major companies that operate in the global transcriptomics market are Agilent Technologies Inc, Bio-Rad Laboratories, F-Hoffmann La-Roche, Fluidigm Corporation, General Electric Company, Illuminia Inc., Merck & Co. Inc, Promega Corporation, QiagenInc, and ThermoFisher Scientific.
By Product& Services Type
By End User